Weimann A, Fronhoff K, Gratz K F, Maschek H, Bartels M, Klempnauer J, Ringe B, Pichlmayr R
Klinik für Abdominal- und Transplantationschirurgie, Medizinischen Hochschule Hannover.
Zentralbl Chir. 1998;123(2):140-4.
While liver hemangioma and focal nodular hyperplasia are not considered an indication for surgery in asymptomatic patients resection has been recommended for hepatocellular adenoma because of the risk of rupture and malignant transformation. Problems arise from differential diagnosis and the appropriate surgical radicality including the indication for liver transplantation. This retrospective analysis deals with 58 patients who underwent surgery for hepatocellular adenoma: resection of different extension: n = 54, liver transplantation n = 4. In 39.6% of the patients the tumor was an incidental finding. In 62.0% of the character of the lesion was unclear prior to surgery. Tumor rupture and bleeding occurred in 17.2%, malignant transformation in 6.9%. Surgical morbidity was 27.6%, mortality 5.2% with the transplant patients alive for 1.5, 7, 9 and 10 years. Two and five years after resection 2 patients developed hepatocellular carcinoma in the liver remnant. The results confirm the indication for surgery in hepatocellular adenoma. Diagnostic approach for solid liver tumors without serum increase of tumor markers should rule out FNH and hemangioma. In all other patients surgery should be considered whenever possible with the radicality of malignant disease. Liver transplantation can be discussed even in asymptomatic patients with multiple adenoma.
虽然肝血管瘤和局灶性结节性增生在无症状患者中不被视为手术指征,但由于存在破裂和恶变风险,肝细胞腺瘤患者建议行手术切除。鉴别诊断以及包括肝移植指征在内的合适手术根治性方面存在问题。这项回顾性分析涉及58例接受肝细胞腺瘤手术的患者:不同范围的切除术:n = 54,肝移植n = 4。39.6%的患者肿瘤为偶然发现。62.0%的患者术前病变性质不明。肿瘤破裂出血发生率为17.2%,恶变率为6.9%。手术并发症发生率为27.6%,死亡率为5.2%,接受移植的患者分别存活了1.5年、7年、9年和10年。切除术后2年和5年,2例患者肝残余组织发生肝细胞癌。结果证实了肝细胞腺瘤的手术指征。对于血清肿瘤标志物无升高的肝脏实性肿瘤,诊断方法应排除局灶性结节性增生和肝血管瘤。在所有其他患者中,只要可能,应按照恶性疾病的根治性原则考虑手术。即使是无症状的多发腺瘤患者,也可讨论肝移植。